For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) ...
Revenues in the fiscal second quarter of 2025 decreased 3% to $201,000, largely due to decreased sales to veterinary clinics.
Power Integrations’ gallium-nitride power-conversion devices rated for 1,700 V marks yet another incursion on markets that, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback